Table 1 Characteristics of the TM-ILP group
From: Lower limb function and quality of life after ILP for soft-tissue sarcoma
Number | Percent | |
|---|---|---|
Total | 27 | 100 |
Tumor entity | ||
Undifferentiated pleomorphic sarcoma | 9 | 33.3 |
Myxoid liposarcoma | 5 | 18.5 |
Synovial sarcoma | 3 | 11.1 |
Leiomyosarcoma | 2 | 7.4 |
Dedifferentiated liposarcoma | 2 | 7.4 |
Myxoid fibrosarcoma | 2 | 7.4 |
MPNST | 1 | 3.7 |
Dedifferentiated chondrosarcoma (extraskeletal) | 1 | 3.7 |
Epithelioid sarcoma | 1 | 3.7 |
Clear-cell sarcoma | 1 | 3.7 |
ILP vascular access level | ||
Iliac | 6 | 22 |
Femoral | 21 | 78 |
Grade of regression according to Salzer-Kuntschik | ||
°1 | 6 | 22.2 |
°2 | 2 | 7.4 |
°3 | 7 | 25.9 |
°4 | 4 | 14.8 |
°5 | 6 | 22.2 |
°6 | 1 | 3.7 |
Missing | 1 | 3.7 |
Local recurrence (LR) after TM-ILP | ||
No LR | 21 | 77.8 |
LR after TM-ILP | 6 | 22.2 |
Treatment due to primary tumor or local recurrence | ||
Primary tumor | 21 | 77.8 |
1st recurrence | 4 | 14.8 |
>1st recurrence | 2 | 7.4 |
Radiotherapy (RT) | ||
No RT | 10 | 37 |
Postoperative RT | 15 | 55.6 |
RT not related to QoL analysis | 2 | 7.4 |